Breaking News, Collaborations & Alliances

Celloram, GENFIT Partner on CLM-022 in Liver Disease

Agreement grants GENFIT exclusive global rights to develop CLM-022 in liver disease indications.

Celloram Inc., a biotech startup that develops novel medicines for cancer and immune disorders, entered into a licensing agreement with French biotech GENFIT SA to advance Celloram’s first-in-class inflammasome inhibitor, CLM-022. The agreement grants GENFIT exclusive global rights to develop CLM-022 in liver disease indications. GENFIT adds to its portfolio of drug candidates for liver disease and gains access to Celloram’s scientists and medicinal chemistry expertise to help syn...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters